Clinical Investigations of CAR-T Cell Therapy for Solid Tumors

23Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Cell therapy is a distinguished targeted immunotherapy with great potential to treat solid tumors in the new era of cancer treatment. Cell therapy products include genetically engineered cell products and non-genetically engineered cell products. Several recent cell therapies, especially chimeric antigen receptor (CAR)-T cell therapies, have been approved as novel treatment strategies for cancer. Many clinical trials on cell therapies, in the form of cell therapy alone or in combination with other treatments, in solid tumors, have been conducted or ongoing. However, there are still challenges since adverse events and the limited efficacy of cell therapies have also been observed. Here, we concisely summarize the clinical milestones of the conducted and ongoing clinical trials of cell therapy, introduce the evolution of CARs, discuss the challenges and limitations of these therapeutic modalities taking CAR-T as the main focus, and analyze the disparities in the regulatory policies in different countries.

Cite

CITATION STYLE

APA

Chen, K., Wang, S., Qi, D., Ma, P., Fang, Y., Jiang, N., … Li, N. (2022, July 18). Clinical Investigations of CAR-T Cell Therapy for Solid Tumors. Frontiers in Immunology. Frontiers Media S.A. https://doi.org/10.3389/fimmu.2022.896685

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free